XOMA Corp
NASDAQ:XOMA

Watchlist Manager
XOMA Corp Logo
XOMA Corp
NASDAQ:XOMA
Watchlist
Price: 27.13 USD 8.04%
Market Cap: 319.6m USD
Have any thoughts about
XOMA Corp?
Write Note

XOMA Corp
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

XOMA Corp
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
XOMA Corp
NASDAQ:XOMA
Other Long-Term Assets
$9.7m
CAGR 3-Years
219%
CAGR 5-Years
65%
CAGR 10-Years
28%
Abbvie Inc
NYSE:ABBV
Other Long-Term Assets
$8.3B
CAGR 3-Years
20%
CAGR 5-Years
44%
CAGR 10-Years
26%
Gilead Sciences Inc
NASDAQ:GILD
Other Long-Term Assets
$7.2B
CAGR 3-Years
15%
CAGR 5-Years
10%
CAGR 10-Years
23%
Amgen Inc
NASDAQ:AMGN
Other Long-Term Assets
$10.4B
CAGR 3-Years
18%
CAGR 5-Years
43%
CAGR 10-Years
21%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Long-Term Assets
$3.2B
CAGR 3-Years
49%
CAGR 5-Years
17%
CAGR 10-Years
95%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Long-Term Assets
$4.1B
CAGR 3-Years
70%
CAGR 5-Years
34%
CAGR 10-Years
31%
No Stocks Found

XOMA Corp
Glance View

Market Cap
318.9m USD
Industry
Biotechnology

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. The company is headquartered in Emeryville, California and currently employs 12 full-time employees. The firm's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The firm's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The firm's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.

XOMA Intrinsic Value
34.8 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is XOMA Corp's Other Long-Term Assets?
Other Long-Term Assets
9.7m USD

Based on the financial report for Sep 30, 2024, XOMA Corp's Other Long-Term Assets amounts to 9.7m USD.

What is XOMA Corp's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
28%

Over the last year, the Other Long-Term Assets growth was 2 336%. The average annual Other Long-Term Assets growth rates for XOMA Corp have been 219% over the past three years , 65% over the past five years , and 28% over the past ten years .

Back to Top